Uncategorized
Lampalizumab is first therapeutic to show efficacy in phase 2 trial for geographic atrophy
KOLOA, Hawaii — Geographic atrophy is estimated to affect more than 5 million patients globally, including 1 million in the United States, and while there is currently no approved treatment, several therapeutics are currently in phase 2 and phase 3 trials, according to a speaker here.“Geographic atrophy (GA) causes irreversible loss of visual function. Lampalizumab is the first potential therapeutic to show evidence of efficacy in a phase 2 trial. There are ongoing trials, and there is a rollover into an open label. Reducing geographic atrophy could, theoretically, change the (Read more...)